Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study

Ann Rheum Dis. 2011 Jun;70(6):1083-6. doi: 10.1136/ard.2010.142042. Epub 2011 Feb 1.

Abstract

Objectives: To assess risk factors for a first thrombotic event in confirmed antiphospholipid (aPL) antibody carriers and to evaluate the efficacy of prophylactic treatments.

Methods: Inclusion criteria were age 18-65 years, no history of thrombosis and two consecutive positive aPL results. Demographic, laboratory and clinical parameters were collected at enrolment, once a year during the follow-up and at the time of the thrombotic event, whenever that occurred.

Results: 258 subjects were prospectively observed between October 2004 and October 2008. The mean ± SD follow-up was 35.0 ± 11.9 months (range 1-48). A first thrombotic event (9 venous, 4 arterial and 1 transient ischaemic attack) occurred in 14 subjects (5.4%, annual incidence rate 1.86%). Hypertension and lupus anticoagulant (LA) were significantly predictive of thrombosis (both at p<0.05) and thromboprophylaxis was significantly protective during high-risk periods (p<0.05) according to univariate analysis. Hypertension and LA were identified by multivariate logistic regression analysis as independent risk factors for thrombosis (HR 3.8, 95% CI 1.3 to 11.1, p<0.05, and HR 3.9, 95% CI 1.1 to 14, p<0.05, respectively).

Conclusions: Hypertension and LA are independent risk factors for thrombosis in aPL carriers. Thromboprophylaxis in these subjects should probably be limited to high-risk situations.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Antiphospholipid / blood
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / immunology
  • Autoantibodies / blood
  • Epidemiologic Methods
  • Female
  • Humans
  • Hypertension / complications
  • Lupus Coagulation Inhibitor / blood
  • Male
  • Middle Aged
  • Thrombosis / etiology*
  • Thrombosis / immunology
  • Thrombosis / prevention & control
  • Young Adult

Substances

  • Antibodies, Antiphospholipid
  • Autoantibodies
  • Lupus Coagulation Inhibitor